Panniculitis during avapritinib therapy for gastrointestinal stromal tumour

Eur J Dermatol. 2023 Dec 1;33(6):703-705. doi: 10.1684/ejd.2023.4632.

Authors

Changhua Zhu¹, Ping Wang², Qinqin Long³, Sheng Lin⁴, Lihang Lin¹, Xuemin Xiao¹

Affiliations

¹ Department of Dermatology, Fujian Medical University Union Hospital, Fuzhou, China.
² Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
³ Department of Pathology, Dermatology Hospital of Fuzhou, Fuzhou, China.
⁴ Department of Rehabilitation, Fuqing City Hospital Fuzhou, Fuzhou, China.

PMID: 38465561
DOI: 10.1684/ejd.2023.4632

No abstract available

MeSH terms

Antineoplastic Agents* / adverse effects
Gastrointestinal Neoplasms*
Gastrointestinal Stromal Tumors* / drug therapy
Gastrointestinal Stromal Tumors* / pathology
Humans
Mutation
Panniculitis* / chemically induced
Protein Kinase Inhibitors / adverse effects
Pyrazoles / therapeutic use
Pyrroles / adverse effects
Receptor, Platelet-Derived Growth Factor alpha / genetics
Receptor, Platelet-Derived Growth Factor alpha / therapeutic use
Triazines*

Substances

avapritinib
Pyrazoles
Pyrroles
Protein Kinase Inhibitors
Antineoplastic Agents
Receptor, Platelet-Derived Growth Factor alpha
Triazines